Xtant Medical Holdings, Inc. (XTNT) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Xtant Medical Holdings, Inc. is a global medical technology company focused on orthobiologics and spinal implant fixation systems. The company operates as a single reportable segment, with approximately 91% of revenue generated in the United States. Xtant is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $35.4 million | $29.9 million | $68.3 million | $57.8 million |
| Gross Profit | $24.3 million | $18.6 million | $44.5 million | $35.9 million |
| Gross Margin | 68.6% | 62.1% | 65.2% | 62.1% |
| Net Income (Loss) | $3.6 million | ($3.9 million) | $3.6 million | ($8.3 million) |
| Diluted EPS | $0.02 | ($0.03) | $0.02 | ($0.06) |
| Cash & Equivalents | $7.0 million (as of June 30, 2025) | |||
| Working Capital | $45.0 million (as of June 30, 2025) | |||
| Long-Term Debt | $22.3 million (net of issuance costs) | |||
| Line of Credit Outstanding | $12.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 18% year-over-year for Q2 2025. This was driven by a 20% increase in orthobiologics sales and the recognition of $5.0 million in license revenue, which was non-existent in the prior year period.
- Profitability: The company returned to profitability, reporting a net income of $3.6 million in Q2 2025 compared to a net loss of $3.9 million in Q2 2024. Operating income improved from a loss of $2.9 million to a profit of $4.6 million.
- Margin Expansion: Gross margin expanded by 650 basis points to 68.6% in Q2 2025, attributed to sales mix, scale, improved production efficiency, and reduced product costs from transitioning to internal production.
- Expense Reduction: Sales and marketing expenses decreased 12% ($1.6 million) due to reduced commission expenses and headcount adjustments. General and administrative expenses decreased 3% ($0.2 million) primarily due to lower stock-based compensation.
- Cash Flow: Net cash provided by operating activities turned positive at $2.6 million for the six months ended June 30, 2025, compared to a use of $10.8 million in the prior year period.
Guidance, Outlook, and Risks
- Strategic Transactions: On July 7, 2025, the company entered into agreements to sell its Coflex/CoFix business in the U.S. and its international hardware subsidiary (Paradigm) to Companion Spine, LLC. The total purchase price is approximately $19.2 million ($17.5M + $1.7M), subject to adjustments. Closing is expected in Q3 2025, contingent on buyer financing.
- Debt Management: Proceeds from the strategic transactions are expected to be used to prepay $9.6 million of the company's term loan.
- Liquidity: Management believes current cash ($7.0 million), operating cash flows, and available credit ($5.0 million remaining on the revolver) are sufficient to meet requirements through August 2026.
- Regulatory Risks: The company faces potential reimbursement changes from the Centers for Medicare & Medicaid Services (CMS) regarding skin substitutes (SimpliMax and SimpliGraft), with new rules potentially effective January 1, 2026. This could impact future revenue recognition for license agreements.
- Ownership Concentration: Nantahala Capital Management, LLC owns approximately 49.1% of the company's common stock, exerting significant control over corporate decisions.
Investor Verification Checklist
- Verify the closing status and financing conditions of the Coflex/CoFix and Paradigm sales to Companion Spine, LLC.
- Monitor the finalization of CMS reimbursement rules for skin substitutes effective January 2026 and their impact on license revenue recognition.
- Review the company's ability to maintain compliance with debt covenants, specifically minimum net product revenue and liquidity levels.
- Assess the sustainability of gross margin improvements as the company transitions more production internally.
- Track the utilization of the $5.0 million remaining availability on the revolving credit facility.